Analysis of Tumor Necrosis Factor (TNF) Inhibitors market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Consumption of tumor necrosis factor inhibitors is expected to rise at a CAGR of 1.3% from 2021 to 2027. In 2020, the global tumor necrosis factor (TNF) inhibitors market was valued at US$ 41.6 Bn, and is anticipated to reach a valuation of US$ 45.5 Bn by the end of 2027.
Tumor Necrosis Factor Inhibitors Market Size (2020)
US$ 41.6 Bn
Projected Year Value (2027)
US$ 45.5 Bn
Global Market Growth Rate (2021-2027)
China Market Growth Rate (2021-2027)
Key Companies Profiled
Demand for the adalimumab drug class is projected to increase at the highest CAGR from 2021 to 2027. Rising R&D expenditure on adalimumab drugs are driving market growth.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
“Rising Prevalence of Autoimmune Diseases to Boost Market Revenue”
As per Fact.MR, a market research and competitive intelligence provider, the global tumor necrosis factor inhibitors market was valued at US$ 41.6 Bn in 2020.
TNF inhibitors are medications that stop the body's physiologic response to tumor necrosis factors, such as the inflammatory response generated by TNF cytokines. Inflammation in the body is caused by TNF-alpha, a crucial component of the autoimmune system.
The market for tumor necrosis factor inhibitors is reaching new heights as the global healthcare industry grows. Tumor necrosis factor blockers are a type of anti-inflammatory drug that is routinely prescribed. Antibodies from human or animal tissues are used to make tumor necrosis factor inhibitor drugs, which are used to treat chronic diseases.
Growing prevalence of autoimmune illnesses such as (RA) rheumatoid arthritis, psoriasis, inflammatory bowel disorder, and Crohn's disease, as well as the increase in the elderly population, are the primary reasons driving the market expansion.
The TNF inhibitors market is projected to expand at a CAGR of 1.3% from 2021 to 2027.
“Advanced Healthcare Facilities & Rapid Deployment of TNF Inhibitor Biosimilars”
The global population is increasingly ageing, especially in developed countries like the United States, Japan, and Western Europe. Developed countries have a higher rate of ageing than undeveloped countries. This is due to the continually improving health infrastructure, reimbursement mechanisms, and innovations in healthcare facilities in these countries.
Furthermore, the availability of a variety of TNF blocker drugs has increased. As a result, people's life expectancies have increased. Tumor necrosis factor inhibitors are popular among the elderly since they help them live longer and healthier lives.
An increase in the number of elderly people leads to a higher risk of sickness, which is expected to drive rising demand for tumor necrosis factor-alpha blockers globally over the coming years.
TNF inhibitor biosimilars are likely to gain market share over the projection period as a result of increased patient affordability in low-income countries and growing patient awareness about the same.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
“High Cost of Tumor Necrosis Inhibitor Drugs & Increase in Alternative Options Restraining Industry Growth”
High production cost of tumor necrosis factor medications, as well as a lack of R&D initiatives, are projected to impede market expansion. The market for tumor necrosis factor inhibitors is expected to be challenged by a rise in the preference for alternative therapies over the forecast period.
The market for TNF inhibitors is predicted to be limited by the negative side effects of inhibitor drugs on patients. Injection site responses, neutropenia, infusion reactions, and infections are among the numerous side effects of TNF inhibition that have been observed in clinical studies and post-marketing surveillance.
The aforementioned factors are expected to limit the global tumor necrosis factor inhibitors market growth over the forecast period.
“Presence of Advanced Healthcare Infrastructure to Propel Market Expansion in North America”
North America is likely to maintain its dominance in the global tumor necrosis factor inhibitors market over the forecast period due to increased development and launches of new medicines in the region.
Presence of superior healthcare infrastructure, a rising frequency of autoimmune disorders in the population, and favorable reimbursement policies are all factors promoting market expansion in North America.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
“Huge Investments by Key Players for Novel Drugs Development Boosting Market Growth”
The U.S. tumor necrosis factor inhibitors market was valued at US$ 11.3 Bn in 2020 and is projected to increase at the highest CAGR over the forecast period. Because of the USFDA's fast drug approval effort, the U.S. has the biggest market share.
Rising prevalence of inflammatory bowel disease (IBD), increasing demand for TNF drugs, and the growing preference for biosimilars are driving the market growth in the U.S. Huge investments by leading players, as well as increase in R&D efforts, are likely to account for a considerable portion of market revenue over the forecast period.
“Proactive Government Initiatives Driving Market Growth”
China is projected to garner a market value of US$ 8.5 Bn by 2027, expanding at a 2.7% CAGR from 2021 to 2027. The China TNF inhibitors market is being driven by the presence of prominent manufacturers, proactive government measures, and the rise in the older population.
Rising rheumatic disease occurrences, improved awareness of the efficacy and availability of TNF inhibitors, higher investments in biosimilars by various industrial companies, and increased regulatory board support for biosimilar approval are projected to stimulate overall market expansion in China.
“Growing Usage of Adalimumab for Wide Range of Inflammatory Disorders Treatment”
Adalimumab is expected to have the largest market share in the drug class segment over the forecast period. Under the commercial name Humira, adalimumab is the first and only completely human monoclonal antibody licenced by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis.
Adalimumab is a drug that is used to treat a wide range of inflammatory disorders in both adults and children, including those that are associated with autoimmune diseases. The activation of a protein called TNF in people with autoimmune disease causes inflammation, which can cause painful and uncomfortable joint swelling, damage, and other forms of inflammation.
Adalimumab is an FDA-approved medication for the treatment of inflammatory autoimmune disorders. Adalimumab is an anti-inflammatory medication used to treat rheumatoid arthritis in people who have moderate to severe symptoms. It works by locating and reducing the source of inflammation that causes joint pain and damage.
“Increasing Need for Rheumatoid Arthritis Treatment Driving Demand for TNF Inhibitor Drugs”
Rheumatoid arthritis holds a significant market share of the tumor necrosis factor inhibitors market because of its widespread prevalence. Rheumatoid arthritis (RA) is a long-term inflammatory disorder of the joints. Inflammation may cause problems with the function and appearance of joints and other body parts. The joints of the fingers of the hand can become dysfunctional as a result of RA.
Rheumatoid arthritis has the highest market share because of rising incidence rates, increased awareness, and a high treatment rate, and it is expected to continue its position with significant growth over the forecast period.
Moreover, RA is more common in women than in men, is predicted to account for around two-thirds of the overall patient population with arthritis, and it worsens with age, all of which are expected to move the market forward.
Almost every industry around the globe suffered a setback due to the COVID-19 pandemic. The COVID-19 pandemic had a severe impact on the tumor necrosis factor inhibitors market. During the pandemic, tumor necrosis factor inhibitors suffered a decrease in sales.
Leading companies have large production facilities and engage in a variety of research and development activities. TNF inhibitors will be in high demand as the frequency of numerous chronic diseases among the elderly rises.
As a result of the increased demand for tumor necrosis factor inhibitors, a number of companies have shifted their focus to new product research and innovation. Hence the tumor necrosis factor inhibitors market is expected to revive over the coming years.
Tumor necrosis factor inhibitor providers are focused on the advancement and production of new products. To minimize side effects, increase their market share, and achieve traction in the global marketplace, market players are developing products using chemically stable ingredients.
For instance :
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesBuy Now
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
The global tumor necrosis factor inhibitors market was valued at US$ 42.1 Bn in 2021.
The Germany TNF inhibitors market in is expected to exhibit 0.4% CAGR over the forecast period.
Increasing prevalence of autoimmune disorders, new product launches of biosimilars, and rise in the geriatric population are driving market growth
The global tumor necrosis factor inhibitors market is expected to rise at a 1.3% CAGR from 2021 to 2027.
The U.S., Canada, Japan, China, and Germany are expected to drive most demand for tumor necrosis factor inhibitors.
AbbVie Inc., Amgen Inc., Innovent Biologics, Inc., Novartis International AG, and Pfizer, Inc. are key tumor necrosis factor inhibitor suppliers.
Need An Exclusive Report For Your Unique Requirement?